Brief: Longboard Pharmaceuticals Successfully Completes Lp352 Multiple Ascending Dose Portion Of Phase 1 Clinical Trial In Healthy Volunteers, Plans To Initiate Phase 1B/2A Clinical Trial
08/09/2021 12:34
Sept 8 (Reuters) - Longboard Pharmaceuticals Inc LBPH.O :
* LONGBOARD PHARMACEUTICALS SUCCESSFULLY COMPLETES LP352
MULTIPLE
ASCENDING DOSE PORTION OF PHASE 1 CLINICAL TRIAL IN HEALTHY
VOLUNTEERS, PLANS TO INITIATE PHASE 1B/2A CLINICAL TRIAL
* LONGBOARD PHARMACEUTICALS INC - CENTRAL 5-HT2C RECEPTOR
ENGAGEMENT DEMONSTRATED BY DOSE- AND EXPOSURE-DEPENDENT
INCREASES OF PROLACTIN
* LONGBOARD PHARMA - PLANS TO INITIATE PHASE 1B/2A CLINICAL
TRIAL
IN ADULT PARTICIPANTS WITH DEVELOPMENTAL AND EPILEPTIC
ENCEPHALOPATHIES IN Q1 2022
Source text for Eikon: ID:nGNX6P4dPr
Further company coverage: LBPH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Longboard Pharmaceuticals
See all newsBrief: Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin In Developmental And Epileptic Encephalopathies (DEEs)
Longboard Pharmaceuticals Inc expected to post a loss of 62 cents a share - Earnings Preview
Brief: Longboard Pharmaceuticals Under Agreement H Lundbeck Required To Pay Co Reverse Termination Fee Of $158.9 Mln In Cash
U.S. RESEARCH ROUNDUP- Cadence Design Systems, Equity Bancshares, S&P Global
Deals of the day-Mergers and acquisitions